cystic fibrosis News
-
Encouraging Results From a Pilot Study Testing the Bionic Pancreas in Cystic Fibrosis Related Diabetes Published in the Journal of Cystic Fibrosis.
Boston, MA-December 3,2019- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world's first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) ...
-
Feldan therapeutics awarded funding by cystic fibrosis foundation
Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis (CF). The award is part of the Cystic Fibrosis Foundation’s US$500 million ...
-
A new paper on the use of Resmon Pro Full to evaluate the effects of airway clearance on patients with cystic fibrosis is available online!
Prof Wallaert and its research group in Belgium used the RESMON PRO FULL to investigate the effects of autogenic drainage technique on ventilatory mechanics in adult with cystic fibrosis. According to the authors: “The FOT opens up new avenues of mechanistic research to understand the pathophysiological effects of airway clearance physiotherapy in CF.”. The ful paper is available ...
By Restech Srl
-
PhysioAssist and the French CF patient association sign a partnership
PhysioAssist and the French CF patient association ‘Vaincre La Mucoviscidose’ have just signed a partnership to facilitate access to the use of the Simeox device at home. We are delighted about this partnership with the association Vaincre La Mucoviscidose, for allowing an easy access without engagement, as well as financial assistance by the association to the patients who wish to ...
By PhysioAssist
-
Abbott awards scholarships to students living with cystic fibrosis to help them pursue their dreams
Abbott today awarded the 2010 Thriving Student Achiever Scholarship to Jason Egbert, a student with cystic fibrosis who demonstrates exceptional academic achievement, community service, creative and artistic talent and passion for inspiring others. Jason Egbert from Rexburg, Idaho, was selected for the Thriving Student Achiever Scholarship from a group of 40 outstanding students with cystic ...
-
BillionToOne to present series of single-gene NIPT posters at 2020 ACMG Annual Clinical Genetics Meeting
BillionToOne, a venture-backed precision diagnostics company, is presenting series of posters at 2020 ACMG Annual Clinical Genetics Meeting on its single-gene NIPT technology and clinical data. UNITY improves clinical specificity for cystic fibrosis carrier screening UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA), sickle cell ...
-
Simeox device is now available in Canada!
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
By PhysioAssist
-
BiomX Announces Corporate Restructuring
Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023 Atopic Dermatitis Program will be delayed due to restructuring BiomX Inc. (NYSE ...
By BiomX
-
Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include ...
-
200 Years of Patient Care. Patient Pioneer: The Story of Courtney Joyce
Last week the hospital marked a significant milestone – the 175th anniversary of the first public demonstration of ether in surgery, considered one of most game-changing events in medical history. In the spirit of that Oct. 16, 1846 landmark, the MGH, fittingly, shares the story of Courtney Joyce, who was the first patient at the hospital to benefit from inhaled nitric oxide (NO) as a ...
-
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients CF Foundation to Invest up to $5 Million in BiomX Common Stock Data Readouts from Phase 1b/2a CF Trial of BX004 Expected in 2022 BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel ...
By BiomX
-
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 ...
By BiomX
-
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
-
New Study Links Cystic Fibrosis with a High Percentage of Patients Infected with Mold
Earlier this month, a new study from the University of Manchester caught the attention of medical professionals and contractors who deal with indoor mold contamination. The study found that almost 50% of adult patients who suffer from cystic fibrosis (CF) are also infected with Aspergillus, a common type of fungi found in the environment and in water damaged buildings. The research examined CF ...
-
Microbion Corporation today announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria (NTM) at the Colorado Mycobacteria Conference 2022: Focus on NTM
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Burkholderia in Healthcare Environments Exposed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses the threat to human health due to Burkholderia cepacia in healthcare environments. Burkholderia cepacia is the name of a group or “complex” of bacteria that can be ...
-
Suketu Upadhyay Elected to Vertex Board of Directors
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life ...
-
Feldan therapeutics announces a publication in nature communications
In an article published in Nature Communications, entitled "Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR Associated Nucleases to Airway Epithelia” Dr. David Guay, Research Director of Feldan Therapeutics, and collaborator Dr. Paul McCray, from the University of Iowa Carver College of Medicine, demonstrate that Feldan’s engineered amphiphilic peptides (Feldan ...
-
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built Facility to support continued R&D growth At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you